A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Mesothelioma
Related studies linked through entity extraction aliases.
Olaparib in People With Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE1
Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)
- Status
- COMPLETED
- Phase
- PHASE2
A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
- Status
- TERMINATED
- Phase
- PHASE2
CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE3
Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Chest Wall Motion Analysis in Disease
- Status
- COMPLETED
- Phase
- N/A
Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
- Status
- COMPLETED
- Phase
- N/A
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1
Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- Status
- COMPLETED
- Phase
- PHASE3
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM
- Status
- TERMINATED
- Phase
- PHASE1
Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3